Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:ASND NASDAQ:ATHA NYSE:JNJ NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$229.76-1.8%$210.77$163.81▼$244.81$405.62B0.516.49 million shs4.10 million shsASNDAscendis Pharma A/S$210.98+3.4%$192.77$118.03▼$214.71$13.00B0.41481,129 shs558,350 shsATHAAthira Pharma$4.34+4.7%$3.91$2.20▼$8.26$17.16M3.0134,761 shs79,629 shsJNJJohnson & Johnson$187.67-0.5%$176.18$140.68▼$189.92$451.70B0.48.92 million shs2.86 million shsJNJJohnson & Johnson$187.67-0.5%$176.18$140.68▼$189.92$451.70B0.48.92 million shs2.86 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+6.03%+10.23%+24.87%+20.47%ASNDAscendis Pharma A/S0.00%+6.28%-0.90%+15.95%+43.02%ATHAAthira Pharma0.00%+7.25%+6.07%+25.42%-2.59%JNJJohnson & Johnson0.00%+4.91%+5.79%+21.44%+17.60%JNJJohnson & Johnson0.00%+4.91%+5.79%+21.44%+17.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$229.76-1.8%$210.77$163.81▼$244.81$405.62B0.516.49 million shs4.10 million shsASNDAscendis Pharma A/S$210.98+3.4%$192.77$118.03▼$214.71$13.00B0.41481,129 shs558,350 shsATHAAthira Pharma$4.34+4.7%$3.91$2.20▼$8.26$17.16M3.0134,761 shs79,629 shsJNJJohnson & Johnson$187.67-0.5%$176.18$140.68▼$189.92$451.70B0.48.92 million shs2.86 million shsJNJJohnson & Johnson$187.67-0.5%$176.18$140.68▼$189.92$451.70B0.48.92 million shs2.86 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+6.03%+10.23%+24.87%+20.47%ASNDAscendis Pharma A/S0.00%+6.28%-0.90%+15.95%+43.02%ATHAAthira Pharma0.00%+7.25%+6.07%+25.42%-2.59%JNJJohnson & Johnson0.00%+4.91%+5.79%+21.44%+17.60%JNJJohnson & Johnson0.00%+4.91%+5.79%+21.44%+17.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.83Moderate Buy$228.22-0.67% DownsideASNDAscendis Pharma A/S 2.88Moderate Buy$244.3615.82% UpsideATHAAthira Pharma 1.00Sell$4.00-7.75% DownsideJNJJohnson & Johnson 2.68Moderate Buy$189.120.77% UpsideJNJJohnson & Johnson 2.68Moderate Buy$189.120.77% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, JNJ, ATHA, ASND, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/6/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$172.00 ➝ $193.0010/6/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$172.00 ➝ $193.0010/3/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$198.0010/3/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$198.0010/3/2025ABBVAbbVieUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$251.0010/3/2025JNJJohnson & JohnsonWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight ➝ Overweight$170.00 ➝ $212.0010/3/2025JNJJohnson & JohnsonWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight ➝ Overweight$170.00 ➝ $212.0010/3/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$220.00 ➝ $251.0010/3/2025JNJJohnson & JohnsonWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$170.00 ➝ $212.0010/3/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$175.00 ➝ $198.0010/3/2025JNJJohnson & JohnsonWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$170.00 ➝ $212.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B7.20$14.67 per share15.66$1.90 per share120.92ASNDAscendis Pharma A/S$393.54M33.07N/AN/A($1.88) per share-112.22ATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/AJNJJohnson & Johnson$90.63B4.99$13.05 per share14.38$29.69 per share6.32JNJJohnson & Johnson$90.63B4.99$13.05 per share14.38$29.69 per share6.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10109.3416.431.376.45%699.66%13.64%10/31/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A879.08N/A-54.94%N/A-24.31%11/13/2025 (Estimated)ATHAAthira Pharma-$96.94M-$15.50N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3520.0616.952.4025.00%32.49%13.00%10/14/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3520.0616.952.4025.00%32.49%13.00%10/14/2025 (Estimated)Latest ABBV, JNJ, ATHA, ASND, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/31/2025Q3 2025ABBVAbbVie$3.26N/AN/AN/A$15.58 billionN/A10/14/2025Q3 2025JNJJohnson & Johnson$2.78N/AN/AN/A$23.73 billionN/A10/14/2025Q3 2025JNJJohnson & Johnson$2.78N/AN/AN/A$23.73 billionN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/7/2025Q2 2025ATHAAthira Pharma-$1.80-$1.80N/A-$0.18N/AN/A7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.562.86%N/A312.38%53 YearsASNDAscendis Pharma A/SN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.77%N/A55.61%64 YearsJNJJohnson & Johnson$5.202.77%N/A55.61%64 YearsLatest ABBV, JNJ, ATHA, ASND, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61ASNDAscendis Pharma A/SN/A1.020.69ATHAAthira PharmaN/A10.8110.81JNJJohnson & Johnson0.501.010.76JNJJohnson & Johnson0.501.010.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ASNDAscendis Pharma A/SN/AATHAAthira Pharma57.12%JNJJohnson & Johnson69.55%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%ASNDAscendis Pharma A/S40.00%ATHAAthira Pharma19.80%JNJJohnson & Johnson0.16%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.77 billionOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableATHAAthira Pharma403.94 million3.16 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableABBV, JNJ, ATHA, ASND, and JNJ HeadlinesRecent News About These CompaniesTrump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants (JNJ)...1 hour ago | marketbeat.comJohnson & Johnson (NYSE:JNJ) Reaches New 52-Week High After Analyst Upgrade5 hours ago | marketbeat.comDid U.S. Orthopaedic Partners’ Medtech Deal Just Shift Johnson & Johnson’s (JNJ) Investment Narrative?5 hours ago | finance.yahoo.comHow J&J's Innovative Medicines Segment is Poised Ahead of Q3 ResultsOctober 6 at 9:37 AM | zacks.comJohnson & Johnson (NYSE:JNJ) Price Target Raised to $193.00 at Sanford C. BernsteinOctober 6 at 8:16 AM | marketbeat.comBalanced Outlook on Johnson & Johnson: Strong Performance Amidst Market Challenges Justifies Hold RatingOctober 6 at 7:11 AM | tipranks.com5 Dividend Kings Are Our Top High-Yield Dividend Picks For OctoberOctober 6 at 6:33 AM | 247wallst.comPenobscot Investment Management Company Inc. Sells 1,532 Shares of Johnson & Johnson $JNJOctober 6 at 4:27 AM | marketbeat.comSignature Wealth Management Partners LLC Buys 6,792 Shares of Johnson & Johnson $JNJOctober 6 at 4:27 AM | marketbeat.comAMF Tjanstepension AB Cuts Holdings in Johnson & Johnson $JNJOctober 6 at 4:27 AM | marketbeat.comLGT Fund Management Co Ltd. Boosts Stock Position in Johnson & Johnson $JNJOctober 6 at 4:27 AM | marketbeat.comApexium Financial LP Reduces Position in Johnson & Johnson $JNJOctober 6 at 4:27 AM | marketbeat.comHudson Valley Investment Advisors Inc. ADV Has $1.66 Million Stake in Johnson & Johnson $JNJOctober 6 at 4:27 AM | marketbeat.com111 Capital Acquires 6,045 Shares of Johnson & Johnson $JNJOctober 6 at 4:19 AM | marketbeat.comAmeriflex Group Inc. Trims Position in Johnson & Johnson $JNJOctober 6 at 4:18 AM | marketbeat.comQRG Capital Management Inc. Raises Position in Johnson & Johnson $JNJOctober 6 at 4:09 AM | marketbeat.comZWJ Investment Counsel Inc. Purchases 1,511 Shares of Johnson & Johnson $JNJOctober 6 at 4:09 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Fortis Capital Advisors LLCOctober 6 at 4:09 AM | marketbeat.comPrecedent Wealth Partners LLC Purchases 1,489 Shares of Johnson & Johnson $JNJOctober 6 at 4:09 AM | marketbeat.comStock Yards Bank & Trust Co. Has $17.15 Million Stock Position in Johnson & Johnson $JNJOctober 6 at 4:09 AM | marketbeat.comJohnson & Johnson $JNJ Stock Position Reduced by Ascent Group LLCOctober 6 at 4:08 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 20253 Dividend Stocks to Hold Through Market Volatility This FallBy Chris Markoch | September 16, 2025Constellation Lowers Outlook: Time to Panic on Buffett's Big Bet?By Leo Miller | September 12, 2025How Berkshire's OxyChem Buy Cements Its Long-Term StrengthBy Jeffrey Neal Johnson | October 2, 2025Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma GiantsBy Gabriel Osorio-Mazilli | October 6, 2025ABBV, JNJ, ATHA, ASND, and JNJ Company DescriptionsAbbVie NYSE:ABBV$229.76 -4.16 (-1.78%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Ascendis Pharma A/S NASDAQ:ASND$210.98 +6.93 (+3.40%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Athira Pharma NASDAQ:ATHA$4.34 +0.20 (+4.73%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Johnson & Johnson NYSE:JNJ$187.66 -0.98 (-0.52%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Johnson & Johnson NYSE:JNJ$187.66 -0.98 (-0.52%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Behind D-Wave's Massive Week (And Why Rivals Also Popped) Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Broadcom’s VMware Push Takes Aim at Microsoft, Google, & Amazon How Berkshire's OxyChem Buy Cements Its Long-Term Strength Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
